D-512

D-512 is a novel, multifunctional small molecule dopamine D2 and D3 receptor agonist currently in pre-clinical development for the treatment of Parkinson's disease. Developed by Dr. Aloke Dutta at Wayne State University, D-512 is designed to offer a dual-action therapeutic approach by providing potent symptomatic relief of motor deficits while simultaneously exerting neuroprotective effects to slow disease progression. In comparative pre-clinical studies, D-512 demonstrated superior and more sustained anti-parkinsonian activity than the commercially available agonist ropinirole, with a significantly lower liability for inducing dyskinesia. Its multifunctional profile is characterized by high-affinity binding to D2 and D3 receptors and potential antioxidant properties that help preserve dopaminergic neurons from oxidative stress-induced loss.